<DOC>
	<DOC>NCT01327612</DOC>
	<brief_summary>The purpose of this protocol is to allow continued treatment with conatumumab and/or AMG 479, with or without chemotherapy to subjects without disease progression whose previous studies were closed.</brief_summary>
	<brief_title>QUILT-3.030: Open Label Extension Study of Conatumumab and AMG 479</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>To be enrolled in this study, subjects must be currently enrolled in a prior Amgensponsored conatumumab or AMG 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without cotherapy), or AMG 479 alone. Subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol Discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab Subjects determined to have disease progression during their participation in the parent Amgen study Woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocolspecified therapy administration Subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocolspecified therapy administration Male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocolspecified therapy administration Subject has previously entered this study Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AMG 655</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Insulin-like Growth Factor</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Modified FOLFOX6</keyword>
	<keyword>mFOLFOX6</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Trail Receptor</keyword>
	<keyword>ganitumab</keyword>
	<keyword>conatumumab</keyword>
</DOC>